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ABSTRACT
Sequence-specific nucleases represent valuable
tools for precision genome engineering.
Traditionally, zinc-finger nucleases (ZFNs) and
meganucleases have been used to specifically edit
complex genomes. Recently, the DNA binding
domains of transcription activator-like effectors
(TALEs) from the bacterial pathogen Xanthomonas
have been harnessed to direct nuclease domains to
desired genomic loci. In this study, we tested a
panel of truncation variants based on the TALE
protein AvrBs4 to identify TALE nucleases
(TALENs) with high DNA cleavage activity. The
most favorable parameters for efficient DNA
cleavage were determined in vitro and in cellular
reporter assays. TALENs were designed to disrupt
an EGFP marker gene and the human loci CCR5 and
IL2RG. Gene editing was achieved in up to 45% of
transfected cells. A side-by-side comparison with
ZFNs showed similar gene disruption activities by
TALENs but significantly reduced nuclease-
associated cytotoxicities. Moreover, the CCR5-
specific TALEN revealed only minimal off-target
activity at the CCR2 locus as compared to the cor-
responding ZFN, suggesting that the TALEN
platform enables the design of nucleases with
single-nucleotide specificity. The combination of
high nuclease activity with reduced cytotoxicity
and the simple design process marks TALENs as a
key technology platform for targeted modifications
of complex genomes.
INTRODUCTION
Designer nucleases have developed into invaluable tools to
modify the genomes of complex organisms. By inserting a
DNA double-strand break (DSB) into the target locus
such nucleases activate DNA repair, which can be har-
nessed to knockout genes or to promote gene targeting
(1,2). Because the DNA damage response is highly
conserved in eukaryotic cells, the concept of DSB-based
genome engineering is easily transferrable between highly
diverse organisms. Accordingly, designer nuclease-based
genome engineering has been successfully established in
more than 10 model organisms thus far, including plants
(3,4), invertebrates (5), ﬁsh (6,7) and mammals (8).
Moreover, the genome of multipotent and pluripotent
human stem cells has been efﬁciently modiﬁed (9–12),
without affecting the differentiation potential of these
cells.
Zinc-ﬁnger nucleases (ZFNs) comprise the most suc-
cessful class of engineered nucleases to date. ZFNs
consist of two functional domains: a customized zinc-
ﬁnger array fused to the non-speciﬁc endonuclease
domain of the well-characterized restriction enzyme
FokI. Upon dimerization of the two ZFN subunits in
correct spacing and orientation, the nuclease domain
cuts the target DNA within the spacer sequence that sep-
arates the two target half-sites (13). In a ﬁrst approxima-
tion, each zinc-ﬁnger within a tandem array recognizes
three bases at the DNA level (14). However, target site
overlap and crosstalk between individual ﬁngers in a
zinc-ﬁnger array considerably complicate the production
of sequence-speciﬁc ZFNs (15), requiring the use of
labor-intense selection procedures to generate zinc-ﬁnger
arrays with sufﬁcient afﬁnity and speciﬁcity (1,16,17). Novel
platforms, such as context-dependent assembly (CoDA),
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ZFNs may not be sufﬁcient for therapeutic applications
(18). Furthermore, although modiﬁcations in the FokI
cleavage domain have been shown to prevent
homodimerization of the individual ZFN subunits
(19–22), the genome-wide speciﬁcity of ZFNs is still
under scrutiny.
The ease of the design process as well as the balance
between nuclease activity and associated toxicity are key
parameters in the application of any type of designer
nuclease (2). Two recent studies identiﬁed a novel
protein scaffold based on transcription activator-like
effector (TALE) proteins isolated from plant pathogens
of the Xanthomonas genus to be amenable for engineering
of customized DNA binding domains (23,24). TALEs are
modular proteins composed of an N-terminal transloca-
tion domain, central repeats that collectively mediate
sequence-speciﬁc DNA binding, and a C-terminal
segment that encompasses nuclear localization signals
(NLS) and a transcriptional activation domain (25). The
central TALE DNA binding domain contains a variable
number (characteristically between 12 and 30) of
conserved 33–35 residues long repeats arranged in
tandem arrays. Polymorphisms between repeats are pre-
dominantly found in positions 12 and 13, also referred to
as the repeat variable di-residues (RVDs), and RVDs that
preferentially recognize one of the four bases in the target
site have been deﬁned (23,24,26,27). Hence, this ‘one
repeat to one base’ code enables the prediction of the
DNA binding sites of natural TALEs or, vice versa, the
engineering of customized TALE repeat arrays that rec-
ognize a user-deﬁned target sequence. As a result, TALE
repeat arrays have attracted great interest as a DNA tar-
geting tool in the context of designer TALE-type tran-
scription factors (dTALEs) (26,28) and TALE nucleases
(TALENs) (27,29–34).
Here, we have characterized the cleavage parameters for
efﬁcient TALEN-mediated genome editing in human cells.
Moreover, we performed a side-by-side comparison
between engineered TALENs and well-characterized
ZFNs at two endogenous human loci, CCR5 and
IL2RG. We show that our designer TALENs can be as
effective as ZFNs in terms of genome editing activity but
signiﬁcantly less cytotoxic. Moreover, our results indicate
that the TALEN platform enables the design of nucleases
with single-nucleotide speciﬁcity. Given both the ease with
which TALENs can be engineered and their superior
toxicity proﬁle, TALENs are likely to have a signiﬁcant
impact on targeted genome engineering in the context of
applied as well as basic biology.
MATERIALS AND METHODS
Plasmids
All TALE derivatives were generated using standard
cloning procedures. The AvrBs4 and AvrBs3 deletion
variants were generated by subcloning a BamHI–BamHI
(A4-BB, A3-BB), Eco147I–HincII (A4-EH), NarI–HincII
(A4-NH, A3-NH), Eco147I–BclI (A4-EC) and NarI–BclI
(A4-NC) fragment of plasmids pENTR-D-avrBs3 and
pENTR-D-avrBs4 (26), respectively, into vectors
pRK5.AD or pRK5.N (35). Where indicated, TALENs
with the obligate heterodimeric KV/EA FokI variants
were used (19). All engineered TALEs were subsequently
cloned into the A4-NH and A4-NC scaffolds. The se-
quences of all TALEs are indicated in Supplementary
Figure S1. The luciferase-based reporter plasmid
(pGLtk.EBEAvrBs4.Luc) is based on plasmid pGLtk (35)
and generated by inserting a tandem repeat of EBEAvrBs4.
The templates for the in vitro cleavage assays were
generated by subcloning an inverted repeat of EBEAvrBs4
separated by variable spacers (from 6–16bp;
Supplementary Table S1) into plasmid
pCMV.LacZqGFP (16). The dsEGFP reporter constructs
used in the episomal gene disruption assay were generated
by cloning homodimeric EBEAvrBs4/AvrBs4 or heterodimeric
EBEAvrBs4/AvrBs3 elements (Supplementary Table S1), re-
spectively, between the ATG and the 50-end of a
destabilized Enhanced Green Fluorescent Protein
(dsEGFP) gene into plasmid pLV.CMV.dsEGFP.
Reporter plasmid pLV.CMV.IL2RG-dsEGFP was
generated by cloning the IL2RG gene derived from
plasmid pRRL.MP.IL2RGpre (kindly provided by Axel
Schambach, Hannover Medical School) into
pLV.CMV.dsEGFP. All ZFN expression vectors were
generated by subcloning a synthesized DNA-binding
domain (GeneArt, Regensburg) into the pRK5.N (35)
vector backbone, which encodes an N-terminal HA tag
followed by a nuclear localization domain, and either of
the obligate heterodimeric FokI variants KV/EA (19). The
target sites and the recognition a-helices of the EGFP (17),
CCR5 (9) and IL2RG-speciﬁc (36) ZFNs have been
described. The complete sequences and maps of all
plasmids can be obtained upon request.
In vitro cleavage assay
In vitro cleavage assays were basically performed as pre-
viously described (21). Brieﬂy, TALENs were expressed
in vitro using the TnT SP6 Quick Coupled
Transcription/Translation System (Promega). The  1-kb
target DNA fragment was generated by Polymerase Chain
Reaction (PCR) with Phusion polymerase (Finnzymes),
primers #78 and #77 (Supplementary Table S2), and
either of the six different plasmids pCMV.LacZ-X-qGFP
(X denoting spacer length) as a template. For in vitro
cleavage, 1ml of each TnT lysate containing one TALEN
subunit was mixed with 200ng of the DNA template and
1mg of BSA in NEBuffer 4 (New England Biolabs) sup-
plemented with 100mM NaCl in a total volume of 10ml.
After incubation for 90min at 37 C the reaction was
analyzed on a 1.2% agarose gel.
Transcriptional reporter assay
All cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% Fetal Bovine Serum
(FBS) and penicillin/streptomycin (Invitrogen).
HEK293T cells were seeded in 24-well plates at a density
of 80 000 cells/well. After 24h, cells were transfected in
duplicate using polyethylenimin (PEI) as described before
(21). Transfection cocktails included 80ng of reporter
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encoding plasmids and 10ng of pRL (Promega) coding
for Renilla luciferase to normalize for transfection efﬁ-
ciency. The amount of DNA was kept constant by
adding pUC118 to 1.2mg. Cells were harvested 48h after
transfection in 1  PLB lysis buffer (Promega). Fireﬂy and
Renilla Luciferases activities were measured in a
luminometer (Berthold Technologies, Bad Wildbach,
Germany) using Dual-Luciferase Reporter Assay System
(Promega) following the manufacturer’s instructions.
Gene disruption and quantitative cell toxicity assays
For episomal gene disruption, 80000 HEK293T cells were
seeded per well of a 24-well plate. After 24h, cells were
PEI transfected with 50ng of pLV.CMV.IL2RG-dsGFP
reporter plasmid, 400ng of nuclease (TALEN, ZFN,
I-SceI) expression plasmid, 50ng of a mCherry expression
vector (kindly provided by Roger Y. Tsien, UC
San Diego) to normalize for transfection efﬁciency,
and pUC118 to 1.2mg. For chromosomal gene
disruption, dsEGFP reporter cells were generated by
lentiviral transduction (LV.CMV.EBEAvrBs4xAvrBs3
.dsGFP; Supplementary Table S1) with a vector dose
that rendered <1% of cells resistant to geneticin-sulfate
(0.4mg/ml), so ensuring that cells contained a single copy
target locus (16). Reporter cells were seeded in 24-well
plates (80000cells/well) and transfected after 24h with
400ng (or 1–600ng) of nuclease expression plasmids,
100ng of a mCherry expression vector, and pUC118 to
1.2mg. After 2 and 5 days, the fractions of mCherry-
positive and EGFP-negative cells were determined by
ﬂow cytometry (FACSCalibur; BD Biosciences). The cell
survival rate was calculated as the decrease in the number
of mCherry-positive cells from Days 2 to 5, normalized to
cells transfected with a non-functional nuclease expression
vector (37).
Genotyping
Genomic DNA of transfected cells was extracted using
QIAamp DNA mini kit (Qiagen). The genomic region en-
compassing the nuclease target sites in dsEGFP or the
human CCR2, CCR5 and IL2RG loci, respectively, were
PCR ampliﬁed (Supplementary Table S2), and amplicons
cleaned up with QIAquick PCR Puriﬁcation Kit (Qiagen).
The DNA fragments were then subjected to digestion with
either XhoI or the mismatch-sensitive T7 endonuclease I
(T7E1; New England BioLabs). For T7E1 assay, DNA
was denatured at 95 C for 5min, slowly cooled down to
room temperature to allow for formation of heteroduplex
DNA, treated with 5U of T7E1 for 15min at 37 C, and
then analyzed by 2% agarose gel electrophoresis.
Immunoblotting
Western blots were performed as described before (21).
TALEN or b-actin were detected with anti-HA tag
(1:2000; Novus Biologicals) or anti-b-actin (1:2000; Cell
Signaling) antibodies, respectively, and visualized with
HRP-conjugated anti-rabbit antibody (Dianova) and
West Pico Chemiluminescence substrate (Thermo
Scientiﬁc).
Statistical analysis
All data sets shown as bar graphs represent the average of
at least three independent experiments. Error bars indicate
standard error of mean (SEM). Statistical signiﬁcance was
determined using a two-tailed, homoscedastic Student’s
t-test.
RESULTS
Minimal DNA binding domain of TALE proteins
The biological function of many Xanthomonas TALE
proteins has been studied extensively and a recent report
identiﬁed a minimal domain required for efﬁcient DNA
binding of the TALE protein Hax3 in human cells (28). In
order to assess whether these ﬁndings can be transferred to
the TALE proteins AvrBs3 and AvrBs4, which were used
as the design scaffold here, we created some corresponding
N- and C-terminal deletion variants (Figure 1a) and fused
them to the transcriptional activation domain of the VP16
protein of the herpes simplex virus (35) (Figure 1b). All
variants contained an N-terminal NLS and a hemagglu-
tinin (HA) tag, which allowed us to monitor the expres-
sion levels of these dTALEs in HEK293T cells by western
blotting (Figure 1c). While the dTALE variants with
extended truncations were expressed to high levels, the
larger variants A3-BB and A4-BB, respectively, revealed
lower steady-state levels. Note, the two-letter code before
the hyphen in the nomenclature of the TALE variants
refer to speciﬁcity: e.g. ‘A4’ in ‘A4-BB’ deﬁnes a TALE
domain that recognizes the predicted 19-bp binding
element of AvrBs4. The two letters following the hyphen
denote the TALE truncation variant, e.g. ‘BB’ in ‘A4-BB’
stands for the BamHI–BamHI fragment, as depicted in
Figure 1a. The ability of the deletion variants to mediate
binding to the predicted 19-bp binding element of AvrBs4
(EBEAvrBs4) was determined in a luciferase-based reporter
assay (Figure 1b). While the deletion variants A4-BB,
A4-NH and A4-NC activated the luciferase reporter con-
struct containing the EBEAvrBs4 sequence motif, reporter
gene activation by A4-EH and A4-EC was indistinguish-
able from the control. Moreover, the AvrBs3-based
variants A3-BB and A3-NH did not activate the
reporter with the EBEAvrBs4 motif, indicating that activa-
tion of the reporter gene by the TALE-type transcription
factors was mediated by a speciﬁc interaction of the
AvrBs4 DNA binding domain with the matching
EBEAvrBs4 sequence motif. Furthermore, these data
conﬁrm that a region encompassing more than 100
residues at the N-terminus of the TALE repeat array is
essential for efﬁcient binding of dTALE proteins to
matching DNA target sequences. In contrast, the
residues located C-terminally with respect to the TALE
repeat domain seem to be dispensable for dTALE–DNA
interaction.
Requirements for efﬁcient DNA cleavage by TALENs
To generate TALE-based nucleases (TALENs), the VP16
transcriptional activation domain was replaced with
the catalytic domain of the FokI endonuclease (38).
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tially determined in an in vitro cleavage assay. A linear
DNA fragment containing an inverted repeat of
EBEAvrBs4 separated by spacers ranging from 6 to 16bp
was incubated with the in vitro translated TALEN
variants (Figure 2a). A recognition site for the
meganuclease I-SceI (39) was included in all target
DNAs as an internal control. In agreement with the tran-
scriptional reporter assay, TALEN variants A4-NH and
A4-NC were able to bind the DNA target and induce
cleavage, while A4-EH and A4-EC were not. Highest
activity was observed by variant A4-NH at spacers of 6,
12 and 16bp. Variant A4-NC, which harbors a longer
protein linker between the TALE repeat units and the
FokI catalytic domain, showed reduced activity.
Although variant A4-BB was expected to cleave substrates
containing the EBEAvrBs4 motif based on the luciferase
reporter assay (Figure 1b), it did not display any
cleavage activity. None of the TALEN variants induced
a DSB in DNA substrates with a single EBEAvrBs4, con-
ﬁrming that TALEN-mediated in vitro cleavage was
sequence speciﬁc and mediated by dimerization of two
TALEN subunits at the speciﬁc target site.
To verify these results in cells, a fast quantitative
reporter assay was developed (Figure 2b). An inverted
EBEAvrBs4 repeat separated by spacers ranging from 6 to
27bp was cloned in between the translational start codon
ATG and the open reading frame (ORF) encoding a
destabilized EGFP (dsEGFP). A recognition site for
I-SceI was included as an internal control. Nuclease
mediated cleavage will either lead to rapid degradation
of the episomal target plasmid or, alternatively, to
error-prone DNA repair by the non-homologous
end-joining (NHEJ) pathway. The resulting reduction in
dsEGFP ﬂuorescence intensity is hence a measure for
nuclease activity. In good agreement with the in vitro
data, expression of TALEN variants A4-NH and
A4-NC led to a considerable reduction of the mean ﬂuor-
escence intensity (MFI) in HEK293T cells transfected with
reporters that contain target sites separated by 12 and
15bp, respectively, but not at other spacer lengths. Note
that some TALEN variants reduced EGFP expression
from the reporter containing a single AvrBs4 recognition
site (single EBE; black bars), suggesting that efﬁcient
binding of these TALENs to the recognition sequence
was sufﬁcient to reduce the MFI between 0 and 20% by
interfering with transcription. A similar observation was
made when expressing a mutated I-SceI (data not shown).
Interestingly, while the A4-NH variant had a restricted
activity proﬁle with a pronounced peak at a 12-bp
spacer, A4-NC was less selective in terms of spacer
length requirements and showed approximately equal
activity on spacers from 12 to 21bp (Figure 2c). Variant
A4-BB displayed notable cleavage activity over back-
ground only on targets with 21 and 27-bp spacers, while
expression of I-SceI reduced dsEGFP expression from all
reporter plasmids. These results support the assumption
that variants with longer linkers need longer spacers to
accommodate the additional amount of protein.
Assessment of TALEN expression (Figure 2d) consistently
revealed reduced steady-state levels of the less active
Figure 1. Minimal DNA binding domain of the AvrBs4 TALE.
(a) Schematic of AvrBs4 and AvrBs3 deletion variants. The black rect-
angles represent the 17.5 central tandem repeat arrays that mediate
DNA recognition. The C-terminal nuclear localization signals (NLS)
and transcriptional activation domain (AD) are highlighted in gray.
Deletion variants are generated using the restriction sites indicated
with letters (B: BamHI; N: NarI; E: Eco147I; H: HincII; C: BclI)
and reported in the respective names (right). The number of remaining
residues at N- and C-termini (relative to the position of the DNA
binding domain) and the RVDs with the expected target sequences
for AvrBs3 and AvrBs4 are shown. (b) Transcriptional reporter
assay. Designer TALE-based transcription factors (dTALEs) consist
of the VP16 transcriptional AD fused to the AvrBs4 or AvrBs3
deletion variants. HEK293T cells were transfected with dTALE expres-
sion plasmids and the reporter construct containing two upstream
binding sites for AvrBs4 (AvrBs4), followed by a minimal promoter
element and the luciferase gene. The graph displays luciferase activity
normalized for transfection efﬁciency and relative to transfection with
empty vector (–). Signiﬁcant activation above background is indicated
by *P<0.05 and **P<0.01. (c) dTALE expression levels. Transfected
HEK293T cells were harvested after 48h and cell lysates probed either
with antibodies against HA tag or b-actin. Lysate of non-transfected
cells is marked with ‘–’.
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not exclusively—explain the lack of activity of these
variants.
Together with the transcriptional reporter data, these
results suggest that the structural requirements for
TALEN-mediated DNA cleavage are divergent from
dTALE-mediated gene regulation, i.e. while the dTALE
variant based on A4-BB activated luciferase expression,
the corresponding TALEN did not efﬁciently cut the
DNA target. Furthermore, variants with a short
C-terminal linker peptide that connects the TALE
repeats with the FokI cleavage domain, such as the 17-
and 47-residue linkers in A4-NH and A4-NC, respectively,
provide a better scaffold to generate designer TALENs.
Proﬁling TALEN activity versus cytotoxicity
To characterize the target site requirements for efﬁcient
cleavage by a heterodimeric TALEN in a chromosomal
context, a HEK293-based reporter cell line with an
integrated dsEGFP cassette was generated. The dsEGFP
ORF contained distinct recognition sites for the TAL ef-
fectors AvrBs3 (EBEAvrBs3) and AvrBs4 (EBEAvrBs4)i n
opposite orientation (Figure 3a). In order to maintain
the ORF and keep an optimal distance between the
EBEs, a 13-bp spacer was chosen. Again, a recognition
site for I-SceI was included as an internal control.
Transfection of these cell lines with expression plasmids
coding for I-SceI or an EGFP-speciﬁc ZFN pair (17)
induced gene disruption in  22% of reporter cells,
Figure 2. Optimal spacer length for DNA cleavage by TALEN. (a) In vitro cleavage activity. TALENs consist of the TALE repeat units preceded by
an HA tag and an NLS. The C-terminal catalytic domain of the FokI endonuclease (FokI) mediates cleavage after dimerization of two TALEN
subunits. The linear DNA substrate containing an inverted AvrBs4 repeat was incubated with TALENs in vitro and the extent of cleavage analyzed
by agarose gel electrophoresis. The respective spacer lengths (left) and the positions of the cleavage products (arrows) are indicated. (b) Cleavage
activity in cellula. HEK293T cells were co-transfected with the respective TALEN expression plasmids and reporter plasmids that harbors an inverted
repeat of AvrBs4 integrated into the 50-end of a gene encoding a destabilized EGFP (dsEGFP). The position of a binding site for I-SceI used for
internal reference is shown. The graph displays reduction of EGFP mean ﬂuorescent intensity (MFI) relative to a non-functional nuclease, as
determined by ﬂow cytometry. The respective spacer lengths separating the AvrBs4 sites are indicated. (c) Relative TALEN activity in relation to
spacer length. The graph displays TALEN activity (from [b]) relative to I-SceI at the various spacers. (d) TALEN expression levels. Transfected
HEK293T cells were harvested after 48h and cell lysates probed either with antibodies against HA tag or b-actin. Lysate of non-transfected cells is
marked with ‘–’.
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co-expression of TALEN subunit A3-NH and A4-NH
was induced in >30% of the transfected cells. Of note,
TALENs that contain an obligate heterodimeric FokI
domain (19), as compared to the wild-type FokI version
used in this experiment, were slightly less active
(Supplementary Figure S2). For both TALENs and
ZFNs gene disruption activity was strictly dependent on
the presence of both nuclease subunits.
The extent of TALEN-mediated target site cleavage in
these reporter cells was subsequently conﬁrmed by
genotyping (Figure 3b). A genomic fragment encompass-
ing the TALE target sites EBEAvrBs3 and EBEAvrBs4 was
ampliﬁed by PCR and subjected to digestion with XhoI.
The XhoI restriction site is located in the spacer sequence
separating the two target half-sites, which is expected to be
cleaved by the TALEN. Given that NHEJ-mediated DNA
repair after a TALEN-induced DSB will frequently lead to
disruption of the target site, the corresponding PCR
amplicons will lack the XhoI recognition site and there-
fore become resistant to XhoI cleavage. The fraction of
XhoI-resistant PCR products reﬂecting the cleavage
activity was in good agreement with the percentage of
EGFP-negative cells (Figure 3a), conﬁrming high
activity of the A3-NH/A4-NH TALEN pair.
To compare directly the activities and
nuclease-associated toxicities of TALENs and ZFNs, the
same reporter cell line was transfected with increasing
amounts of expression vectors ranging from 1 to 600ng
of each subunit (Figure 3c). Note that while the TALEN
pair was equipped with a wild-type FokI domain, the
ZFNs contain an obligate heterodimeric cleavage
domain that was shown to reduce nuclease-associated
toxicity (19,21). The activity proﬁles of both classes of
nucleases were comparable for any of the DNA amounts
transfected and reached a maximal gene disruption
activity at about 45% EGFP-negative cells. However, as-
sessment of cell survival 5 days after transfection revealed
a signiﬁcant increase in cytotoxicity for ZFN transfected
cells at high vector doses.
Figure 3. Comparison of activity versus toxicity proﬁles of TALEN
and ZFN. (a) Designer nuclease-mediated gene disruption. The
HEK293-based reporter cells harbor an integrated dsEGFP gene that
contains an inverted heterodimeric AvrBs4/AvrBs3 target sequence
Figure 3. Continued
separated by 13-bp spacer in the 50-end of the open reading frame. The
position of the diagnostic XhoI site is indicated. For internal reference,
a binding site for I-SceI was placed downstream of the TALEN target
site. The graph shows the percentage of EGFP-negative cells 5 days
after transfection with the nuclease expression vectors (TALEN, ZFN
or I-SceI). (b) Molecular characterization. Genomic DNA was ex-
tracted 5 days after transfection and PCR amplicons encompassing
the target sites were used as templates for digestion with XhoI. An
arrow indicates the position of the XhoI-resistant DNA fragment.
The numbers below designate the percentages of XhoI-resistant PCR
fragments (note background level of  6%). (c) Activity versus toxicity.
The EGFP reporter cells were transfected with increasing amounts
(1–600ng) of nuclease expression vectors (TALEN, ZFN or I-SceI)
and a mCherry-encoding plasmid. The percentage of EGFP and
mCherry-positive cells was determined by ﬂow cytometry after 2 and
5 days. The graphs display gene disruptions activities (EGFP-negative
cells at Day 2; top) and nuclease-associated cytotoxicities (fraction of
mCherry-positive cells at Day 5 as compared to Day 2 after transfec-
tion; bottom), relative to cells transfected with a mock plasmid.
Statistically signiﬁcant differences in toxicities between TALEN and
ZFN are indicated by *P<0.05 or **P<0.01, respectively.
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that the optimal spacer length for TALENs based on the
A4-NH scaffold is 12 or 13bp, while the A4-NC architec-
ture, which contains a longer linker between the DNA
binding domain and the C-terminal FokI domain, was
more ﬂexible with respect to spacer length. In summary,
our data demonstrate that TALEN-mediated gene disrup-
tion at chromosomal loci can be as efﬁcient as knockouts
created by ZFNs but with reduced nuclease-associated
toxicity.
Efﬁcient disruption of endogenous genes
Based on the above ﬁndings, we aimed at generating
TALEN pairs that target endogenous genes in the
human genome. To this end, we designed TALENs to
target sites in the CCR5 and IL2RG loci (Figures 4
and 5) that overlap with previously published ZFN recog-
nition sites (20,40). The corresponding TALE repeat
domains were cloned into both the A4-NC (47-residue
linker) and A4-NH (17-residue linker) scaffolds and
termed GC-NC or GC-NH (targeted to the IL2RG
locus) and C5-NC or C5-NH (targeted to the CCR5
locus). Note that while the ZFN half-sites are separated
by 5bp, the TALEN target sites contain 15-bp spacers.
For quantitative comparison of the activities and
toxicities of the IL2RG-speciﬁc TALEN (designated
‘GC’ for gamma chain) and ZFN, an IL2RG-dsEGFP
reporter construct was generated (Figure 4b). A recogni-
tion site for I-SceI was placed in between the two ORFs as
a reference. Co-transfection of the reporter with I-SceI,
the IL2RG-speciﬁc TALENs or ZFN expression vectors,
respectively, reduced the MFI of IL2RG-dsEGFP
between 69% and 90%. This demonstrated that all of
the tested nucleases were highly active, although the
TALEN variant GC-NC with the longer linker was
somewhat more active than GC-NH. Concomitant assess-
ment of cytotoxicity, on the other hand, revealed an
almost 2-fold increase in cell survival when comparing
the GC-NC TALEN versus the ZFN pair, respectively.
To assess activity of GC-NC at the genome level,
HEK293T were transfected with the respective TALEN
or ZFN expression vectors (Figure 4c). The extent of
NHEJ induced insertions/deletions after target site
cleavage was quantiﬁed using the mismatch-sensitive
T7E1 endonuclease (41). A direct comparison indicated
that the engineered IL2RG-speciﬁc TALEN pair was
about half as active as the well-established ZFN, with
targeted allelic modiﬁcation frequencies of 14% for the
TALEN and 37% for the ZFN. A CCR5-speciﬁc
TALEN served as a negative control at the IL2RG locus.
Then the TALENs designed to target the CCR5 locus,
C5-NC and C5-NH (Figure 5a), were transfected into
HEK293T. Genomic DNA was isolated and subjected to
T7E1-based genotyping. A side-by-side comparison
indicated that the engineered C5-NC TALEN was as
active as the well-established ZFN, with allelic modiﬁca-
tions at 17 and 14%, respectively (Figure 5b). As seen
before for the IL2RG-speciﬁc TALENs, the C5-NH
TALEN with the shorter linker was not as active as
C5-NC.
Speciﬁcity of designer nucleases is an important param-
eter. A major off-target locus of the CCR5-speciﬁc ZFN
has been identiﬁed in CCR2 (40,42), which shares a high
degree of sequence identity with the CCR5 locus
(Figure 5c). The ZFN target site in CCR5 differs from
the corresponding site in CCR2 in two positions, one in
each target half site. In contrast, the entire 19-bp target
sequence of the left TALEN subunit is also found in
CCR2 while the right target half-site varies at only one
position bound by a TALE repeat unit and an additional
Figure 4. Modiﬁcations at the human IL2RG locus. (a) Target sites in
human IL2RG gene. Target sites are highlighted by gray shaded
(TALEN) or black (ZFN) boxes, respectively. The RVDs of the engin-
eered TALEs as well as the expected target sequences are indicated.
(b) Comparison of the activities and toxicities of IL2RG-speciﬁc
designer nucleases. HEK293T cells were co-transfected with expression
plasmids-encoding IL2RG-speciﬁc TALEN and ZFN, respectively, and
a reporter plasmid harboring an IL2RG-dsEGFP fusion gene. The
graphs display reduction of the mean ﬂuorescent intensity (MFI) of
IL2RG-dsEGFP (left) and relative cell survival as compared to cells
expressing a nonfunctional nuclease indicated with ‘–’ (right). NH and
NC designate the TALEN scaffold used. Statistically signiﬁcant
differences in activity and toxicity between the TALEN and ZFN
tested are indicated by *(P<0.05) or **(P<0.01), respectively. (c)
Disruption of endogenous human IL2RG locus. After transfection
with TALEN (NC scaffold) and ZFN expression vectors, genomic
DNA was extracted and used as a template for PCR ampliﬁcation.
Amplicons encompassing the target sites were digested with the
mismatch-sensitive T7 endonuclease 1 (T7E1). Arrows indicate
the expected positions of the T7E1 digestion products. Numbers at
the bottom designate the average percentage of modiﬁed alleles
(n=2). TALENs targeting the CCR5 locus (C5-TALEN) were used
as negative controls. L and R refer to the nuclease subunits, binding
to the left or right target half-sites, respectively.
Nucleic Acids Research, 2011,Vol.39, No. 21 9289one recognized by the 0th repeat (Figure 5a). T7E1-based
genotyping at the CCR2 locus revealed that expression of
the CCR5-speciﬁc ZFN-induced mutations at 11% of
CCR2 alleles, while only 1% of CCR2 alleles were
mutated after TALEN expression. Parallel assessment of
cytotoxicity revealed a 2-fold increase in cell survival when
comparing the CCR5-speciﬁc TALEN with the ZFN pair
(Figure 5d).
DISCUSSION
Designer nucleases have evolved into invaluable tools for
targeted genome engineering. In particular, ZFNs have
been successfully employed in a broad variety of
research ﬁelds, ranging from fundamental to applied
science. A major drawback of ZFNs, however, is the elab-
orate and time-consuming experimental selection process
(1,17). Although simpliﬁed methods, such as modular
assembly and CoDA have been reported (18,43,44), the
quality of ZFNs generated by such platforms is contro-
versial (45–47) or not determined yet. In this study, we
have characterized the cleavage parameters for 17.5
repeats containing TALENs based on the AvrBs4
scaffold. This TALEN scaffold mediates binding to a
total of 19bp, including the invariant thymine (in
position–1) that precedes the RVD-deﬁned nucleotides
in the TALE target box (24). By employing different
in vitro and cellular reporter assays, we have deﬁned a
TALEN architecture that allows for efﬁcient DNA
cleavage. Depending on the length of the linker that
connects the TALE DNA binding domain with the FokI
cleavage domain, we found that spacers of 12–15bp
between the two target half-sites are optimal for high
TALEN cleavage activity.
Similar to our approach, Miller et al. (27) produced a
set of TALENs with truncated TALE domains. Their
variants with 28 or 63 residue long C-terminal linkers
proved to be the most active conﬁgurations and are
similar to our A4-NH and A4-NC scaffolds with 17-
and 47-residue linkers, respectively. In the context of
TALE transcription factors, Zhang et al. (28) showed
that 147 residues N-terminally of the TALE repeat units
are essential for efﬁcient DNA binding. This is in good
agreement with our A4-NH and A4-NC scaffolds (+153
amino acids) as well as the architecture used by Miller
et al. (27). Although we barely detected activity of our
longer TALEN variant A4-BB, TALENs similar to this
scaffold have been used in other studies (32,33). Given
that the respective TALEN activities in these reports
were determined using different methods, in different or-
ganisms, and at target sites with longer spacers that may
accommodate the longer linkers, it is difﬁcult to compare
the results directly. Nonetheless, our data imply that a
very long stretch of residues between the TALE repeat
units and the FokI nuclease domain may place the cata-
lytic center in an unfavorable position that impairs
activity. Alternatively, lower nuclease activity of the
longer TALEN variants is simply a result of decreased
protein stability, as shown in our immunoblots.
Figure 5. Modiﬁcations at the human CCR5 locus. (a) Target sites in
human CCR5 gene. Target sites are highlighted by gray shaded
(TALEN) or black (ZFN) boxes, respectively. The RVDs of the engin-
eered TALEs as well as the expected target sequences are shown. Bold
letters designate the nucleotides not conserved in the CCR2 locus.
(b) Disruption of endogenous human CCR5 locus. After transfection
with TALEN and ZFN expression vectors, genomic DNA was ex-
tracted and PCR amplicons encompassing the CCR5 target sites
digested with T7E1. Arrows point out the expected positions of the
T7E1 digestion products. Numbers at the bottom indicate the
average percentage of modiﬁed alleles (n=3). TALENs targeting
the IL2RG locus (GC-TALEN) were used as a negative control.
NH and NC designate the TALEN scaffold. (c) Off-target activity at
CCR2 locus. Asterisks in the alignment of CCR5 and CCR2 designate
the mismatches between the two target sequences, bold letters the
nucleotides affecting binding of the designer nucleases. PCR amplicons
encompassing the CCR2 target locus were digested with T7E1. Arrows
point out the expected positions of the T7E1 digestion products.
Numbers at the bottom designate the average percentage of modiﬁed
alleles (n=2). (d) Cytotoxicity of CCR5-speciﬁc designer nucleases.
The graph displays nuclease-associated cytotoxicities relative to cells
expressing a nonfunctional nuclease (–). Statistically signiﬁcant differ-
ences in toxicities between TALENs and ZFN are indicated by
**P<0.01.
9290 Nucleic Acids Research, 2011,Vol.39, No. 21Some of the aforementioned studies also explored in
detail the spacer length requirements between the two
target half-sites. In accordance with studies performed
on ZFNs (48,49), the protein linker that connects the
DNA binding domain with the nuclease domain inﬂuences
selectivity with regard to DNA spacer length and hence
ultimately speciﬁcity. While TALENs with long linkers
(>200 amino acids) seem to work on a very broad range
of spacers spanning 14–40bp (29,30), the shorter linkers
(17–63 residues) used in our study and in Miller et al. (27)
restrict activity to spacers of 12–22bp. Nonetheless, these
results are in sharp contrast to ZFNs where activity can be
restricted to 5/6-bp spacers using a short 4-residue linker
(49), so more effort in optimizing the architecture of
TALEN has to be invested to further restrict the activity
range of these nucleases in the future.
The design process to generate TALENs is based on a
simple modular assembly strategy. As opposed to ZFNs,
in which an individual zinc-ﬁnger module contacts in a
ﬁrst approximation a 3-bp target subsite (14), each
TALE repeat unit recognizes a single nucleotide (23,24).
We have used the four RVDs NN to target guanine, NI
for adenine, NG for thymine and HD for cytosine. Some
recent reports showed a stronger preference of the NK
repeat to bind guanine than NN (26,27), so it will be inter-
esting to see whether exchanging the respective RVDs will
increase activity and further reduce toxicity of designer
TALENs.
Overall, the success rate for generating TALENs by
simple modular assembly seems very high. We have
used the natural TALEs AvrBs4 and AvrBs3 in the
context of a TALEN pair to disrupt an EGFP marker
and designed two additional TALEN pairs that recognize
target sites in two endogenous sites in the human genome.
These nucleases induced modiﬁcations in 14 or 17% of the
targeted IL2RG or CCR5 alleles, respectively, or 45% of
the EGFP reporter. These numbers are comparable to
data reported by Miller et al. (27) who generated
TALENs based on a different TALE backbone and
different numbers of TALE repeats. The authors
targeted the human CCR5 and NTF3 genes with
efﬁciencies of up to 27% and report that all of their
TALEN pairs designed to recognize sites with a
12–21bp spacer yielded at least 5% gene editing (27).
Furthermore, Cermak et al. (32) described design guide-
lines based on natural TALEs that may further improve
the success frequency.
To enable a side-by-side analysis with ZFNs, the en-
dogenous target sites in CCR5 and IL2RG were chosen
to overlap with binding sites of previously described ZFNs
(20,40). On the whole, our designed TALENs showed
similar gene disruption activities as some extensively
optimized ZFNs, such as the CCR5-speciﬁc ZFN pair
that has been employed in two clinical trials
(NCT00842634, NCT01044654). On the other hand, the
TALENs used here were generally less cytotoxic than their
ZFN counterparts, suggesting better speciﬁcity. In fact, in
a side-by-side analysis of the CCR5-speciﬁc designer nu-
cleases, the TALEN showed signiﬁcantly reduced
off-target activity at the CCR2 locus as compared to the
ZFN. Remarkably, the CCR5-speciﬁc TALEN induced
mutations at 17% of CCR5 alleles and at only 1% of
the highly homologous CCR2 locus. In contrast, activity
of the CCR5-speciﬁc ZFN was almost comparable at the
two loci, with mutation frequencies of 14% at CCR5 and
11% at CCR2. For both ZFN and TALEN the respective
target sites differ at two positions each: 2 out of 24nt for
the ZFN and 2 out of 38nt for the TALEN pair. One of
the two mismatches between CCR5 and CCR2 coincides
with the 50 terminal T of the right TALE binding box
(Figure 5a). Previous studies have shown that this T in
position  1 of the recognition site pairs with the
postulated 0th TALE repeat and is critical for the
TALE–DNA interaction (24,50). Although further
studies are needed, it seems that the conserved 50 T nu-
cleotide of the EBE sites are particularly well-suited to
discriminate two nearly identical target sites.
As mentioned above, all TALEN pairs used in this
study recognize a 38-bp target site while the binding
sites for the corresponding ZFNs were 18 or 24bp long.
While much more work will be required to come to deﬁni-
tive conclusions, it is tempting to speculate that the gen-
erally longer recognition sites of TALENs as compared to
ZFNs go along with higher speciﬁcities and therefore less
toxicity.
Depending on the speciﬁc needs, other functional
domains can be fused to the TALE repeat units to
create artiﬁcial proteins able to modify not only the
genome, but also the epigenome or transcriptome in a
targeted fashion. The high success rates of the TALE
modular assembly strategy to produce functional
designer nucleases or artiﬁcial transcription factors (26–
28,32,33,51) suggest that context-dependent effects
between individual TALE repeat units are negligible.
The high number of repeat units with their high degree
of homology does complicate the assembly of such DNA
binding domains when using standard cloning
approaches. However, recently introduced Golden Gate
based strategies overcome these limitations (28,32,33,51).
Given the high interest in sequence-speciﬁc genome
surgery, it is conceivable that off-the shelf TALENs for
each human gene will be available soon.
In conclusion, the TALEN scaffold presented here
enables genome editing with high efﬁciency and precision.
A side-by-side comparison between our TALENs and
well-characterized ZFNs showed that the TALE
platform enables the design of artiﬁcial nucleases
that are as effective as the ZFNs in terms of activity
but likely more speciﬁc and less cytotoxic. Although
further characterization with regard to speciﬁcity will
be necessary for clinical applications of TALENs, the
simple 1:1 code, i.e. one TALE repeat unit recognizing
1nt, will greatly facilitate the design of customized DNA
binding domains for basic and applied sciences in the
future.
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